Track topics on Twitter Track topics that are important to you
Despite being heralded as lower-cost alternatives to branded biologics, the approval of biosimilar therapies for chronic diseases is not likely to yield expected cost savings due to a number of state and payer policies, according to an opinion piece published in JAMA.However, cost-savings may be attainable after key challenges to biosimilar substitution are overcome, the authors concluded.
Original Article: Biosimilars unlikely to save costs as expected, experts sayNEXT ARTICLE
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...